{
  "actions": [
    {
      "acted_at": "2019-04-02",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2019-04-02",
      "action_code": "H11100",
      "committees": [
        "HSJU"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on the Judiciary.",
      "type": "referral"
    },
    {
      "acted_at": "2019-05-15",
      "action_code": "",
      "committees": [
        "HSJU"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr2038-116",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Judiciary",
      "committee_id": "HSJU"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Judiciary",
      "committee_id": "HSJU",
      "subcommittee": "Subcommittee on Administrative State, Regulatory Reform, and Antitrust",
      "subcommittee_id": "05"
    }
  ],
  "congress": "116",
  "cosponsors": [
    {
      "bioguide_id": "B001305",
      "district": "13",
      "name": "Budd, Ted",
      "original_cosponsor": false,
      "sponsored_at": "2019-04-15",
      "state": "NC",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "L000589",
      "district": "8",
      "name": "Lesko, Debbie",
      "original_cosponsor": false,
      "sponsored_at": "2019-10-17",
      "state": "AZ",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2019-04-02",
  "number": "2038",
  "official_title": "To allow State-based, market-oriented, prescription drug negotiations to lower pharmaceutical drug prices, to encourage competition, to increase consumer choice and access, and for other purposes.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "s4796-116",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr8527-116",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    }
  ],
  "short_title": "State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019",
  "sponsor": {
    "bioguide_id": "M001187",
    "district": "11",
    "name": "Meadows, Mark",
    "state": "NC",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2019-04-02",
  "subjects": [
    "Cancer",
    "Child health",
    "Child safety and welfare",
    "Congressional oversight",
    "Drug, alcohol, tobacco use",
    "Health",
    "Health care costs and insurance",
    "Health care coverage and access",
    "Health facilities and institutions",
    "Health personnel",
    "Health programs administration and funding",
    "Long-term, rehabilitative, and terminal care",
    "Prescription drugs",
    "Rural conditions and development",
    "Sales and excise taxes",
    "State and local finance"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2019-04-02",
    "date": "2020-12-31T17:25:27Z",
    "text": "State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019\n\nThis bill authorizes health insurance issuers to jointly negotiate the prices for prescription drugs with the manufacturers of such drugs."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To allow State-based, market-oriented, prescription drug negotiations to lower pharmaceutical drug prices, to encourage competition, to increase consumer choice and access, and for other purposes.",
      "type": "official"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019",
      "type": "short"
    }
  ],
  "updated_at": "2022-11-01T19:02:23Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/hr/BILLSTATUS-116hr2038.xml"
}